Medicine Overview of Ovalac 500mg Tablet
Ovalac is an antiviral medicine used in the treatment of herpes labialis, genital herpes infection and herpes zoster infections. It prevents the multiplication of virus in human cells and clears up the infection.
Ovalac should be taken in the dose and duration as advised by your doctor. Do not skip any doses and finish the full course of treatment even if you feel better. It may be taken with or without food, but it is better to take it at a fixed time. If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. You should drink plenty of water while on treatment with this medicine as it helps to prevent dehydration and kidney damage.
It may lead to a few common side effects like headache, nausea and stomach pain. Inform your doctor if these side effects persist for a longer duration. Please consult your doctor if you are pregnant, planning to conceive or breastfeeding.
- Herpes labialis
- Genital herpes infection
- Herpes zoster
- Headache
- Nausea
- Abdominal pain
-
Do not skip any doses and finish the full course of treatment even if you feel better.
-
Drink plenty of water while on treatment with this medicine. This helps to prevent dehydration and kidney damage.
-
If you have genital herpes, use barrier methods (condoms) for contraception and avoid sexual contact while the sores are present.
-
Inform your doctor if you are pregnant or planning to conceive or breastfeeding.
Oral
Herpes zoster (shingles)
Adult: 1 g tid for 7 days. Immunocompromised patients: Continue treatment for a further 2 days after crusting of lesions.
Herpes simplex infections of skin and mucous membranes; Genital herpes
Adult: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes.
Prophylaxis of cytomegaloviral infections in immunocompromised patients
Adult: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days.
Herpes labialis
Adult: 2 g 12 hrly for 1 day.
Suppression of recurrent herpes simplex
Adult: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy.
Herpes simplex infections of skin and mucous membranes; Genital herpes
Child: >12 yr: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes.
Prophylaxis of cytomegaloviral infections in immunocompromised patients
Child: >12 yr: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days.
Herpes labialis
Child: >12 yr: 2 g 12 hrly for 1 day.
Suppression of recurrent herpes simplex
Adult:
Child: >12 yr: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy.
Chickenpox
<2 years: Safety and efficacy not established
>2 years: 20 mg/kg PO q8hr for 5 days; not to exceed 1 g PO q8hr
Herpes labialis
CrCl 30-49 mL/min: 1 g PO q12hr for 1 day
CrCl 10-29 mL/min: 500 mg PO q12hr for 1 day
CrCl <10 mL/min: 500 mg PO once
Herpes zoster
CrCl 30-49 mL/min: 1 g PO q12hr
CrCl 10-29 mL/min: 1 g/day PO
CrCl <10 mL/min: 500 mg/day PO
Genital herpes (initial episode)
CrCl 10-29 mL/min: 1 g/day PO
CrCl <10 mL/min: 500 mg/day PO qDay
Genital herpes (recurrent episodes)(suppressive therapy, immunocompetent patients)
CrCl <29 mL/min: 500 mg/day PO
Patient at risk of dehydration. Renal impairment. Pregnancy and lactation. Patient Counselling Avoid sexual intercourse when symptoms of genital herpes are present. Monitoring Parameters Monitor renal, hepatic and haematological functions.
Lactation: Drug excreted in breast milk; use with caution
>10%
Headache (14-35%),Neutropenia (<18%),Elevated aspartate transaminase (AST) (2-16%),Nasopharyngitis (<16%),Nausea (6-15%),Elevated alanine transaminase (ALT) (<14%),Abdominal pain (2-11%)
1-10%
Dysmenorrhea (1-8%),Depression (<7%),Arthralgia (<1-6%),Vomiting (<1-6%),Dizziness (2-4%),Rash (<8%),Rhinorrhea (<2%),Thrombocytopenia (<3%),Leukopenia (<1%)
<1%
Agitation,Aggression,Alopecia,Confusion,Erythema multiforme,Hypertension,Tachycardia,Tremor,Visual disturbances
Potentially Fatal: Hepatitis; renal failure; blood dyscrasias; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Reviews
Clear filtersThere are no reviews yet.